F4

Ada Health extends Series B to $120 million to accelerate rapid growth

Retrieved on: 
Thursday, February 10, 2022
Bertelsmann Printing Group, Penguin Random House, Growth, AI, Arvato, Consultant, Farallon Capital, Traction, Solution, Investment, NEW, BMG, COVID-19, Patient, Technology, F4, Diagnosis, Series, Novartis, USD, CEO, Private equity, Health, Organization, RTL Group, VC, UNPRI, Sutter Health, RRW, BI, Vitruvian Partners, Partner, Digital, Christie's, Security (finance), Pharmaceutical industry, Medical device, Renewable energy, Publishing, Financial services, Bayer, Ada Health, Bertelsmann

BERLIN, LONDON and NEW YORK, Feb. 10, 2022 /PRNewswire/ -- Ada Health GmbH ('Ada'), the Berlin-based digital health company, today announces that it has closed its Series B round at $120 million by raising a $30 million extension round. The new funding will enable Ada to accelerate its growth and strengthen its presence in the US, following strong interest and traction in that market.

Key Points: 
  • Schroders Capital acquires secondary shares through public and private vehicles
    BERLIN, LONDON and NEW YORK, Feb. 10, 2022 /PRNewswire/ -- Ada Health GmbH ('Ada'), the Berlin-based digital health company, today announces that it has closed its Series B round at $120 million by raising a $30 million extension round.
  • Torsten Schero, Chief Financial Officer at Ada Health, said:
    "We are thrilled to have these high-profile investors joining Ada as we accelerate our rapid international growth.
  • On the back of Ada Health's successful series B, Schroders Capital has acquired secondary shares for over $30 million through public and private vehicles.
  • The Ada platform has 11 million users worldwide, and has completed 26 million assessments since its global launch in 2016.

Siemens Healthineers Launches Enhanced Liver Fibrosis (ELF) Test in the U.S.

Retrieved on: 
Wednesday, January 26, 2022
Health, General Health, F4, Risk, EBIT, NYSE, Non-alcoholic fatty liver disease, Patient, Cedars-Sinai Medical Center, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASH, Liver, Biopsy, Fatty liver disease, Cirrhosis, Diabetes, Cell damage, Siemens Healthineers, Hope, Gastroenterology, FDA, NAFLD, LH, DGX, ELF, End organ damage, Prognosis, Food, Obesity, Solution, HIV disease progression rates, Inflammation, Disease, De novo, Quest Diagnostics, Medical device, Medical imaging, LabCorp

The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool.

Key Points: 
  • The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool.
  • NASH affects up to 20 million people in the U.S., and is predicted to be the leading indication for liver transplant by 20301.
  • The ELF Test uses a routine blood sample and mathematical algorithm to generate a score that assesses the risk of disease progression.
  • Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care.

Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH

Retrieved on: 
Tuesday, October 19, 2021
Fast Track, Fibrosis, Fatty liver disease, Metabolism, Risk, Private Securities Litigation Reform Act, COVID-19, NASH, Liver transplantation, U.S. Securities and Exchange Commission, Fast track (FDA), F4, Security (finance), Adult, Annual report, Disease, SAN, EFX, FGF21, FDA, Therapy, GLOBE, Patient, Liver failure, Nature Medicine, F2, SEC, Food, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, Trial of the century, Pharmaceutical industry

(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program investigating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH).

Key Points: 
  • (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program investigating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH).
  • The Fast Track designation facilitates the development of new drugs to treat serious conditions where there is an unmet medical need.
  • This designation enables more frequent interactions with the FDA and potential eligibility for priority review if clinical data support it.
  • The FDA Fast Track designation for EFX is an important step forward in potentially bringing EFX to the growing number of patients impacted by NASH, said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero.

Healthy Extracts Begins New Clinical Trial to Investigate Ability of UBN RELIEF™ to Naturally Alleviate Migraine Symptoms and Improve Cognitive Function

Retrieved on: 
Wednesday, September 22, 2021
Dizziness, Attention, News, Clinical trial, OTCQB, Â, UBN, Achievement, Risk, Memory, Annual report, Person, F4, Sale, Private Securities Litigation Reform Act, Health, Cognitive behavioral therapy, Water, FDA, Western Colorado Center for the Arts, Polyphenol, Coffee, Migraine, Nausea, Ketone, Heart, IP, BrainScope Company, Inc., Caffeine, Ultimate Brain, Company, Biomedical Advanced Research and Development Authority, Disease, Cognition, Research, Brain, Forward-looking statement, Flavonoid, Light, Doctor of Philosophy, SEC, GLOBE, Dietary supplement, Pharmaceutical industry, Fine chemical

The new clinical trial will build upon the success of an initial study published last December in the World Journal of Advanced Research and Reviews .

Key Points: 
  • The new clinical trial will build upon the success of an initial study published last December in the World Journal of Advanced Research and Reviews .
  • UBN RELIEF is based on a specialized version of Healthy Extracts proprietary, patent-protected Fuel4Thought (F4T) formulation.
  • It is the result of more than 20 years of scientific research, including more than 100 clinical studies on the key ingredients.
  • The formulation includes highly concentrated medium chain triglycerides, F4T MCT, which are derived from Healthy Extracts patent pending extraction process.

Published Study Shows Healthy Extracts Breakthrough Nutraceutical Formulation, ACTIVATE, Naturally Enhances Key Brain Activity by 46%

Retrieved on: 
Tuesday, September 14, 2021
Risk, Water, Ketone, Achievement, Heart, Ultimate Brain, FDA, OTCQB, Forward-looking statement, F4, Polyphenol, UBN, Attention, Company, Private Securities Litigation Reform Act, Cognitive behavioral training, Disease, Annual report, Caffeine, IP, Food, Brain, Â, Memory, Person, GLOBE, Flavonoid, Cognition, SEC, Sale, News, Coffee, BrainScope Company, Inc., Medical imaging, Dietary supplement, Pharmaceutical industry, Fine chemical

Publication of this study represents an incredible contribution to the food and nutrition industry, especially regarding the effectiveness of our nootropics ACTIVATE, stated Healthy Extracts president, Duke Pitts.

Key Points: 
  • Publication of this study represents an incredible contribution to the food and nutrition industry, especially regarding the effectiveness of our nootropics ACTIVATE, stated Healthy Extracts president, Duke Pitts.
  • These published results validate the benefits that can be derived from our expanding portfolio of natural nutrient formulations for brain health and cognition.
  • The formulation includes highly concentrated medium chain triglycerides, F4T MCT, which are derived from Healthy Extracts patent pending extraction process.
  • The companys subsidiaries, BergametNA and Ultimate Brain Nutrients (UBN), offer nutraceutical natural heart and brain health supplements.

Healthy Extracts Introduces Ultimate Brain Nutrients RELIEF™ for Migraine Sufferers, a Breakthrough Natural Treatment Clinically Shown to Reduce Symptom Duration by 61% and Frequency by 39%

Retrieved on: 
Tuesday, August 31, 2021
Company, OTCQB, Migraine, Private Securities Litigation Reform Act, Quality of life, Polyphenol, GLOBE, SEC, Memory, Research, Ketone, Nausea, Person, Disease, F4, Flavonoid, Heart, Forward-looking statement, Sport, Risk, Achievement, Cognition, Dizziness, Attention, Biomedical Advanced Research and Development Authority, News, UBN, IP, Ultimate Brain, NIH, Genta (company), Light, Cognitive behavioral therapy for insomnia, FDA, Sale, Water, Brain, Annual report, Coffee, Caffeine, American College, Pharmaceutical industry, Dietary supplement, Fine chemical

This special formulation of all-natural ingredients was designed to reduce symptoms related to migraines, while helping to maintain healthy neurological function, stated Healthy Extracts president, Duke Pitts.

Key Points: 
  • This special formulation of all-natural ingredients was designed to reduce symptoms related to migraines, while helping to maintain healthy neurological function, stated Healthy Extracts president, Duke Pitts.
  • According to the NIH , there is no cure for migraines, with severe, debilitating attacks often coming on quickly and unexpectedly.
  • Migraine drugs are also nowhere near 100% effective and have numerous potential adverse side effects, resulting in non-adherence to prescribed medications.
  • The companys subsidiaries, BergametNA and Ultimate Brain Nutrients (UBN), offer nutraceutical natural heart and brain health supplements.

Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results

Retrieved on: 
Tuesday, August 24, 2021
Company, Record, U.S. Securities and Exchange Commission, GLOBE, Regenerative medicine, SEC, Method, Knowledge, Research, Fas ligand, B cell, CPA, F4, Risk, R, APOP, Intellectual property, Cell, Forward-looking statement, CFO, American, G&A, Review, Clinical trial, NASDAQ, Mass meeting, Patient, NIS, FDA, Annual report, American depositary receipt, Technology, Security (finance), Fine chemical, Pharmaceutical industry, Coal, Lithium

Tel Aviv, Israel, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2021, and provided an update on the proposed strategic merger with privately-held Quoin Pharmaceuticals and recent clinical news

Key Points: 
  • Separately, Yaron Ben-Oz, CPA, will be joining the Company as Chief Financial Officer, effective September 1, 2021.
  • General and administrative (G&A) expenses for the second quarter were $0.86 million compared to $0.65 million in the 2020 second quarter.
  • Finance expenses for the second quarter of 2021 were $0.43 million compared to finance expenses of $1.63 million in the second quarter of 2020.
  • Total comprehensive loss for the second quarter was $1.7 million, or $0.004 per share compared total comprehensive loss of $2.7 million, or $0.007 per share, in the second quarter of 2020.

Healthy Extracts Introduces Revolutionary On-the-Go Gel Packs of Clinically Proven Heart, Brain and Immune Health Formulations Using Patented Gel Technology

Retrieved on: 
Tuesday, August 24, 2021
Industry, Company, OTCQB, CAGR, Private Securities Litigation Reform Act, Extract, Superfood, Polyphenol, Technology, Motivation, GLOBE, SEC, Gel, Method, Memory, Ketone, Citrus, Person, Disease, F4, Metabolic syndrome, Absorption, Flavonoid, Heart, Forward-looking statement, Bergamot, Tablet, Risk, Achievement, Cognition, Attention, News, UBN, Digestion, Creativity, Coffee, IP, Ultimate Brain, Powder, ASEA (American company), Sale, FDA, Water, Brain, Cholesterol, Annual report, Choking, Caffeine, Dietary supplement, Perfume, Vaccine, 3D printing, Pharmaceutical industry, Fine chemical

Among the many benefits, the new gel pack format will make Healthy Extracts products easier and more convenient to consume.

Key Points: 
  • Among the many benefits, the new gel pack format will make Healthy Extracts products easier and more convenient to consume.
  • However, a single-serving, bio-degradable Healthy Extracts gel pack containing these health-promoting formulations can be easily consumed anytime, anywhereno liquid or mixing required.
  • Healthy Extracts has introduced industry game changers with its clinically proven formulas for improving heart, brain and immune health, noted Gelteq CEO, Nathan Givoni.
  • Healthy Extracts plans to next introduce heart and immune health gel packs that exclusively feature the world's strongest Citrus Bergamot SuperFruit extract.

Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Friday, August 13, 2021
Trial of the century, Inflammation, U.S. Securities and Exchange Commission, Clinical trial, Fatty liver disease, F4, Research, SAN, FGF21, F2, Liver failure, Risk, Private Securities Litigation Reform Act, Disease, F3, COVID-19, Therapy, GLOBE, Nature Medicine, NASH, SEC, GMP, EFX, Annual report, Patient, Security (finance), Fibrosis, Metabolism, API, Safety, Cirrhosis, Liver injury, Pharmaceutical industry, Risk management

(Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported second quarter financial results for the period ending June 30, 2021.

Key Points: 
  • (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported second quarter financial results for the period ending June 30, 2021.
  • During the second quarter, Akero continued to enroll patients in the HARMONY study, a Phase 2b multicenter, randomized, double-blind, placebo-controlled, clinical trial in biopsy-confirmed pre-cirrhotic NASH patients (fibrosis stages F2 and F3).
  • During the second quarter, Akero successfully initiated GMP manufacture of drug substance (API) to be used for Phase 3 evaluation of EFX.
  • Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies.

89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 12, 2021
Liver, Fatty liver disease, Administration, Trial of the century, Histology, Disclosure, F4, FGF21, Research and development, Research, The O.C., Goal, SAN, Private Securities Litigation Reform Act, COVID-19, GLOBE, R, NASH, SEC, Health, Hypertriglyceridemia, Patient, Investment, Â, Growth, Fibrosis, PK, G&A, Safe harbor, Safety, Cirrhosis, Pharmaceutical industry

SAN FRANCISCO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended June 30, 2021.

Key Points: 
  • SAN FRANCISCO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended June 30, 2021.
  • In the second quarter of 2021, we continued to execute on our goals and took important steps in advancing BIO89-100 as a new treatment option for patients suffering from NASH, said Rohan Palekar, Chief Executive Officer of 89bio.
  • 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
  • 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.